- Previous Close
1.8000 - Open
1.7903 - Bid 1.3300 x 200
- Ask 2.3500 x 100
- Day's Range
1.7771 - 1.9150 - 52 Week Range
1.4100 - 36.0000 - Volume
11,700 - Avg. Volume
466,912 - Market Cap (intraday)
2.784M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-48.2000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.00
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
www.60degreespharma.comRecent News: SXTP
View MorePerformance Overview: SXTP
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SXTP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SXTP
View MoreValuation Measures
Market Cap
2.71M
Enterprise Value
7.42M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.88
Price/Book (mrq)
--
Enterprise Value/Revenue
14.77
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-89.67%
Return on Equity (ttm)
-181.78%
Revenue (ttm)
681.35k
Net Income Avi to Common (ttm)
-7.95M
Diluted EPS (ttm)
-48.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
3.39M
Total Debt/Equity (mrq)
3.94%
Levered Free Cash Flow (ttm)
-4.26M